$CELG Recent News A teachable moment: Here are my worst

New Post Public Reply Private Reply Replies (0) Message Board

Dec 23, 2014 at 1:05 PM

$CELG Recent News

A teachable moment: Here are my worst stock picks of 2014 10:19 a.m. Today - Jeff Reeves
Four signs that would indicate a new uptrend 2:52 p.m. Dec. 16, 2014 - The Trading Deck
Liquid growth stocks tell interesting tale 3:11 p.m. Dec. 9, 2014 - The Trading Deck
H&R Block shares fall on quarterly miss 6:42 p.m. Dec. 8, 2014 - Wallace Witkowski
The S&P 500 recorded its biggest drop in nearly 7 weeks 4:33 p.m. Dec. 8, 2014 - Anora Mahmudova
Celgene shares climb 1.9% 9:31 a.m. Dec. 8, 2014 - Sue Chang
Is the next Cisco out there? 3:24 p.m. Nov. 25, 2014 - The Trading Deck
5 charts show how stock repurchases boost prices 6:00 a.m. Nov. 18, 2014 - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt

Dow Tops 18000 48 min ago - The Wall Street Journal Interactive Edition
Seattle Genetics And Agios Pharmaceuticals: Opportunity Or Danger? 11:21 a.m. Today - Seeking Alpha
Celgene (CELG) Weak On High Volume Today 10:02 a.m. Today - TheStreet.com
RBC’s 5 Top Biotech Stocks to Buy for 2015 9:07 a.m. Today - 247WallSt.com
5 Healthcare Stocks to Buy 4:04 a.m. Today - InvestorPlace.com
Express Scripts Picks AbbVie HCV Drugs Over Gilead 4:59 p.m. Dec. 22, 2014 - Investors Business Daily
Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst Blog 3:20 p.m. Dec. 22, 2014 - Zacks.com
Jim Cramer Answers Twitter (TWTR) Questions on Gilead, WhiteWave Foods, and More 1:37 p.m. Dec. 22, 2014 - TheStreet.com
Trade of the Day: IBB Up 40% YTD – Buy, Sell or Hold? 7:17 p.m. Dec. 21, 2014 - InvestorPlace.com
Juno Therapeutics IPO Hot As Cancer Curers In Demand 5:32 p.m. Dec. 19, 2014 - Investors Business Daily
Merrill Lynch Top Healthcare Stock Picks for 2015 2:00 p.m. Dec. 19, 2014 - 247WallSt.com
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo 10:53 a.m. Dec. 19, 2014 - Seeking Alpha
Cramer: ‘Downside’ to Biotech as ImmunoGen Stock Cut in Half 10:46 a.m. Dec. 19, 2014 - TheStreet.com
Europe advisory committee supports expanded label for Revlimid 9:16 a.m. Dec. 19, 2014 - Seeking Alpha
European Panel Gives Positive Opinion on Celgene Cancer Drug 8:59 a.m. Dec. 19, 2014 - The Wall Street Journal Interactive Edition
Celgene (CELG) Leads The Pack In Pre-Market Activity 8:37 a.m. Dec. 19, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: 10 Reasons We'll Have a Santa Claus Rally 8:10 p.m. Dec. 18, 2014 - TheStreet.com
'Mad Money' Lightning Round: GE Is a Good Stock With Good Yield 6:00 a.m. Dec. 18, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Why This Market Is All About Velocity 8:16 p.m. Dec. 17, 2014 - TheStreet.com
Trade of the Day: More Gains to Come in Top-Ranked CELG Stock 7:20 p.m. Dec. 17, 2014 - InvestorPlace.com

Critical Alerts For Invensense, FireEye, General Electric, Twitter and Celgene Released By InvestorsObserver 9:31 a.m. Dec. 22, 2014 - PR Newswire - PRF
Scanning Biotech Equities -- Celgene, Novavax, Amarin, Immunomedics, and Aeterna Zentaris 8:40 a.m. Dec. 17, 2014 - PR Newswire - PRF
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers 8:00 a.m. Nov. 20, 2014 - BusinessWire - BZX
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV 4:29 p.m. Nov. 19, 2014 - Marketwired
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV 3:35 p.m. Nov. 19, 2014 - Marketwired
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PowerBank Bags Key Solar Project, Eyes Major Gains

A New Milestone for PowerBank Sometimes, out of the blue, a company bags a contract that seems to shift the momentum overnight. That's what's happening with PowerBank Corporation. They've just scored a big win with a contract from SUNY Oneonta to build a 1.6 MW ground-mount solar project. Talk about striking gold in the solar energy field! A Competitive Win Procuring this...

Graphic Packaging Names Berardinelli as HR Executive

A New Chapter in HR Leadership at Graphic Packaging September 8 marks a turning point for Graphic Packaging Holding Company with the appointment of Tatiana Berardinelli as their new Chief Human Resources Officer. As NYSE:GPK positions itself for ambitious growth, Berardinelli stands out for her knack for managing transformations and building cultures that thrive in...

Nasdaq Flashes Warning Signs for Scage Future's Compliance

Two Strikes from Nasdaq: A Wake-Up Call? Scage Future's getting a double-shot of reality from Nasdaq after slipping under crucial thresholds. Here's the score: Scage's been dinged on their Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS). Over a stretch from mid-July to late August, these benchmarks floundered below the line. The...

Art Ave Spurs Rebirth in Downtown DC: A Template for Revival

Turning Streets into Art Galleries No one would have believed a stretch of DC's bureaucratic offices was about to morph into a vibrant destination worthy of major art aficionados. But here we are, tipping our hats to the Golden Triangle Business Improvement District (BID), who just snagged the IDA Downtown Achievement Award of Excellence for their Art Ave project. Not...

Hello Group Posts Q2 Earnings with Mixed Signals

Q2 Revenue Slump Amid Profit Recovery No sugarcoating it, revenue numbers for Hello Group Inc. (NASDAQ:MOMO) are less than stellar for the second quarter of 2026. Net revenues fell 5.1% year-over-year to RMB2,486.0 million (about $366.4 million). Not exactly what you want to see in a growth-oriented tech company. However, what’s really worth your attention is the net...

UNISORB Expands Reach with BILZ Acquisition

UNISORB Acquisition: A Game-Changer for Industrial Solutions This ain't the first time a company took over another to expand its footprint, but UNISORB's latest move to scoop up BILZ-USA is worth a closer look. Everybody's talking about this takeover that throws UNISORB right into the spotlight of North America's industrial sector. Naming them the exclusive distributor of...

Mitrade EU Enhances Investor Safety with New Insurance

Mitrade's New Insurance: A Safety Net? Mitrade EU is amping up its game with some fresh insurance perks that catch the eye. They're slapping on some extra insolvency protection for clients trading under their CySEC license. Now that sounds like a financial shield anyone would want. Basically, they're adding another layer to the basic regulatory protections, and without...

Huawei Unleashes Bold New Flagship Devices in Munich

Huawei's Bold Move in Munich When I hear about yet another product launch, I often roll my eyes but this one, folks, deserves a second glance. Huawei dropped a news bomb in Munich with their 'Chase the Wild' event, unveiling a huge lineup of flagship gadgets. This isn't your run-of-the-mill release; the mix of smart wearables, tablets, smartphones, and audio gear marks...

Texas Institute Leads Trailblazing Arrhythmia Study

Breaking New Ground in Heart Rhythm Treatment Well, here's a twist that even the stock market folks might envy—pioneering innovation in healthcare. This time, it’s not about tech stocks or a bull market, but about real human lives. The Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center in Austin has jumped to the forefront by participating in a...

AEC Firms Revamp Strategies Amid Talent Tug-of-War

The State of Compensation in AEC Sit back and chew on this—AEC firms are playing a whole new ball game when it comes to compensating their talent. FMI Corporation’s 2026 Compensation Trends Study is putting a spotlight on what really goes on behind the scenes in architecture, engineering, and construction firms. This is about more than just tossing some coin for a...